Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May;25(18):2000603.
doi: 10.2807/1560-7917.ES.2020.25.18.2000603.

Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samples

Anne J Jääskeläinen  1 , Eliisa Kekäläinen  1 , Hannimari Kallio-Kokko  1 , Laura Mannonen  1 , Elisa Kortela  2 , Olli Vapalahti  1 , Satu Kurkela  1   3 , Maija Lappalainen  1   3
Affiliations

Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samples

Anne J Jääskeläinen et al. Euro Surveill. 2020 May.

Abstract

Antibody-screening methods to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) need to be validated. We evaluated SARS-CoV-2 IgG and IgA ELISAs in conjunction with the EUROLabworkstation (Euroimmun, Lübeck, Germany). Overall specificities were 91.9% and 73.0% for IgG and IgA ELISAs, respectively. Of 39 coronavirus disease patients, 13 were IgG and IgA positive and 11 IgA alone at sampling. IgGs and IgAs were respectively detected at a median of 12 and 11 days after symptom onset.

Keywords: COVID-19; IgA; IgG; SARS-CoV-2; commercial; serology.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

Figures

Figure 1
Figure 1
Distribution of IgG and IgA ratio values (Euroimmun) from COVID-19 patients according to time after first positive PCR test result, Finland, 2020 (n = 39 patients)
Figure 2
Figure 2
SARS-CoV-2 IgG and IgA ELISA ratio values (Euroimmun) and RT-qPCR Ct values from concurrent serum and nasopharyngeal samples, Finland, 2020 (n = 14)
Figure 3
Figure 3
SARS-CoV-2 IgG and IgA ELISA ratio values (Euroimmun) from COVID-19 patients with data of disease severity and days after onset of symptoms, Finland, 2020 (n = 37)
See this image and copyright information in PMC

References

    1. European Centre for Disease Prevention and Control (ECDC). Coronavirus disease 2019 (COVID-19) in the EU/EEA and the UK – ninth update, 23 April 2020. Stockholm: ECDC; 2020. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-rapid-...
    1. Eurosurveillance Editorial Team Latest updates on COVID-19 from the European Centre for Disease Prevention and Control. Euro Surveill. 2020;25(6):2002131. - PMC - PubMed
    1. World Health Organization (WHO). Coronavirus disease (COVID-19) Pandemic. Geneva: WHO. [Accessed 28 Mar 2020]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
    1. Spiteri G, Fielding J, Diercke M, Campese C, Enouf V, Gaymard A, et al. First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020. Euro Surveill. 2020;25(9):2000178. 10.2807/1560-7917.ES.2020.25.9.2000178 - DOI - PMC - PubMed
    1. World Health Organization (WHO). Laboratory testing of 2019 novel coronavirus (‎‎‎‎‎‎‎‎‎‎‎‎2019-nCoV)‎‎‎‎‎‎‎‎‎‎‎‎ in suspected human cases: interim guidance, 17 January 2020. Geneva: WHO; 17 Jan 2020.

Publication types

MeSH terms